Profile data is unavailable for this security.
About the company
PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.
- Revenue in AUD (TTM)866.18k
- Net income in AUD-8.90m
- Incorporated2000
- Employees52.00
- LocationPharmaust Ltd96-100 Albert Road, Level 4SOUTH MELBOURNE 3205AustraliaAUS
- Phone+61 39692-7222
- Fax+61 89467-6111
- Websitehttps://www.pharmaust.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Starpharma Holdings Ltd | 9.76m | -8.17m | 43.82m | 50.00 | -- | 1.54 | -- | 4.49 | -0.0198 | -0.0198 | 0.0237 | 0.0682 | 0.2195 | 0.244 | 1.20 | -- | -18.37 | -27.20 | -24.10 | -33.05 | 93.52 | 77.48 | -83.69 | -269.74 | 4.58 | -- | 0.1115 | -- | 131.84 | 29.10 | 47.79 | -- | -22.29 | -- |
| Oncosil Medical Ltd | 387.46k | -12.38m | 45.41m | 2.00 | -- | 8.71 | -- | 117.19 | -0.0056 | -0.0056 | 0.0002 | 0.0014 | 0.0435 | -- | 0.2937 | -- | -138.79 | -68.47 | -170.28 | -78.28 | -256.87 | -- | -3,193.94 | -800.23 | -- | -38.98 | 0.0152 | -- | -9.95 | -36.76 | -9.10 | -- | -- | -- |
| Medical Developments International Ltd | 33.15m | -40.99m | 50.70m | 68.00 | -- | 0.8718 | -- | 1.53 | -0.4627 | -0.4627 | 0.3741 | 0.5162 | 0.4131 | 1.02 | 4.14 | -- | -51.09 | -15.81 | -60.56 | -17.79 | 73.50 | 70.98 | -123.66 | -52.49 | 1.82 | -- | 0.0476 | -- | 2.51 | 9.22 | -630.83 | -- | -20.32 | -- |
| Next Science Ltd | 34.20m | -19.81m | 56.97m | -- | -- | 5.48 | -- | 1.67 | -0.0738 | -0.0738 | 0.1255 | 0.0356 | 1.97 | 5.34 | 8.04 | -- | -113.88 | -74.40 | -168.92 | -90.31 | 78.83 | 76.98 | -57.93 | -128.26 | 1.96 | -- | 0.1045 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| Radiopharm Theranostics Ltd | 299.23k | -47.95m | 69.53m | -- | -- | 0.5238 | -- | 232.38 | -0.1261 | -0.1261 | 0.0008 | 0.0611 | 0.0041 | -- | 0.1097 | -- | -65.24 | -- | -82.85 | -- | -- | -- | -16,024.17 | -- | -- | -3.46 | -- | -- | 2.35 | -- | -38.54 | -- | -- | -- |
| PharmAust Limited | 866.18k | -8.90m | 87.56m | 52.00 | -- | 7.83 | -- | 101.08 | -0.0234 | -0.0199 | 0.0023 | 0.023 | 0.1004 | -- | 10.39 | -- | -103.16 | -31.15 | -118.57 | -35.11 | -- | -- | -1,027.49 | -105.37 | -- | -- | 0.00 | -- | -8.78 | -27.63 | -466.09 | -- | -- | -- |
| Recce Pharmaceuticals Ltd | 5.24m | -17.66m | 114.65m | -- | -- | -- | -- | 21.89 | -0.0999 | -0.0999 | 0.0296 | -0.0467 | 1.17 | -- | 41.87 | -- | -395.76 | -136.12 | -- | -226.28 | -- | -- | -337.29 | -373.28 | -- | -19.86 | -- | -- | 18.17 | 50.13 | -35.06 | -- | 9.55 | -- |
| EZZ Life Science Holdings Ltd | 66.44m | 6.96m | 128.80m | -- | 18.04 | 6.04 | 17.51 | 1.94 | 0.1607 | 0.1607 | 1.54 | 0.4801 | 3.08 | 13.79 | 33.30 | -- | 32.25 | 24.12 | 38.61 | 31.19 | 76.67 | 65.40 | 10.48 | 9.81 | 5.63 | 482.42 | 0.0058 | -- | 78.88 | 42.81 | 91.87 | 53.25 | 176.34 | -- |
